Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Cellectis S.A.. (4/12/17). "Press Release: Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.".

Organisations Organisation Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
  Organisation 2 Calyxt Inc. (Nasdaq Global Market: CLXT)
  Group Cellectis (Group)
Products Product TALEN (Transcription Activator-Like Effector Nuclease)
  Product 2 plant biotechnology
Persons Person Moore, Jennifer (Cellectis 201511 VP Communications)
  Person 2 Harnest, Simon (Cellectis 201505 VP Finance + Investor Relations before Trout Group)
     


Cellectis (Alternext: ALCLS; Nasdaq: CLLS) today announces that it is exploring the possibility of an initial public offering (IPO) of a minority interest in its plant sciences business, Calyxt, Inc. No decisions have been taken at this point on the structure or timing of any IPO, and no assurance can be given that an IPO will be pursued.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.


This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.


For further information, please contact:

Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com

IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com

   
Record changed: 2017-04-18

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Cellectis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top